Byers Eye Institute at Stanford University
Byers Eye Institute at Stanford University
Palo Alto, California, United States11 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Electrical Stimulation for Vision Neuroenhancement in Glaucoma | eye disorder, glaucoma, ocular hypertension, open-angle glaucoma | Recruiting | Not applicable | 2026-10-09 | NCT06685211 | |
| Suprachoroidal Administration in Subjects With Metastases to the Choroid | Neoplasms by Site, eye disorder, neoplasm, ocular cancer | Recruiting | Phase 2 | 2026-10-08 | NCT06643884 | |
| Intravitreal Faricimab Injections or Fluocinolone Acetonide (0.19 mg) Intravitreal Implants vs Observation for Prevention of VA Loss Due to Radiation Retinopathy | Neurologic Manifestations, Pathological Conditions, Signs and Symptoms, Sensation Disorders, Signs and Symptoms, Visual Impairment, eye disorder, nervous system disorder, vision disorder | Recruiting | Phase 3 | 2026-08-20 | NCT05844982 | |
| An Efficacy, Safety, and Tolerability Study of VRDN-003 in Participants With Active Thyroid Eye Disease (TED) | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Eye Diseases, Hereditary, Graves Ophthalmopathy, Graves disease, autoimmune disease, disease of orbital part of eye adnexa, endocrine system disorder, exophthalmos, eye disorder, goiter, hereditary disease, hyperthyroidism, immune system disorder, thyroid gland disorder | Active, not recruiting | Phase 3 | 2026-08-18 | NCT06625411 | |
| An Efficacy, Safety, and Tolerability Study of VRDN-003 in Participants With Chronic Thyroid Eye Disease (TED) | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Eye Diseases, Hereditary, Graves Ophthalmopathy, Graves disease, autoimmune disease, disease of orbital part of eye adnexa, endocrine system disorder, exophthalmos, eye disorder, goiter, hereditary disease, hyperthyroidism, immune system disorder, thyroid gland disorder | Active, not recruiting | Phase 3 | 2026-08-18 | NCT06625398 | |
| Topical Insulin for Glaucoma (TING2) | Glaucoma, Primary Open Angle, exfoliation glaucoma, exfoliation syndrome, eye disorder, glaucoma, iris disorder, low tension glaucoma, ocular hypertension, open-angle glaucoma, optic nerve disorder, uveal disorder | Not yet recruiting | Phase 1 / Phase 2 | 2026-06-02 | NCT07619482 | |
| A Registry of Subjects With Primary Indeterminate Lesions or Choroidal Melanoma | Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Uveal Neoplasms, eye disorder, malignant choroid melanoma, melanocytic neoplasm, melanoma, neoplasm, neuroendocrine neoplasm, ocular cancer, primitive neuroectodermal tumor, uveal disorder, uveal melanoma | Active, not recruiting | Not stated | 2026-05-22 | NCT03941379 | |
| Sensory Substitution and Brain Plasticity Following Vision Loss | Neurologic Manifestations, Pathological Conditions, Signs and Symptoms, Sensation Disorders, Signs and Symptoms, blindness (disorder), eye disorder, nervous system disorder, vision disorder | Not yet recruiting | Not applicable | 2026-03-05 | NCT07450677 | |
| Topical Insulin for Glaucoma | eye disorder, glaucoma, ocular hypertension | Recruiting | Phase 1 | 2025-11-25 | NCT05206877 | |
| Dual Intravitreal Implantation of NT-501 Encapsulated Cell Therapy for Glaucoma | eye disorder, glaucoma, ocular hypertension | Active, not recruiting | Phase 2 | 2025-11-04 | NCT04577300 | |
| Study of NT-501 Encapsulated Cell Therapy for Glaucoma Neuroprotection and Vision Restoration | eye disorder, glaucoma, ocular hypertension | Active, not recruiting | Phase 2 | 2025-11-04 | NCT02862938 |